LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel: Apples and pears serve the same purpose: Better diagnosis for anaphylaxis.

    Çolak, Sevgi / Erkoç, Merve / Sin, Betül A / Bavbek, Sevim

    The World Allergy Organization journal

    2023  Band 16, Heft 10, Seite(n) 100822

    Sprache Englisch
    Erscheinungsdatum 2023-10-06
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2581968-9
    ISSN 1939-4551
    ISSN 1939-4551
    DOI 10.1016/j.waojou.2023.100822
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: Comparison of two diagnostic criteria in the diagnosis of anaphylaxis in a tertiary adult allergy clinic.

    Çolak, Sevgi / Erkoç, Merve / Sin, Betül A / Bavbek, Sevim

    The World Allergy Organization journal

    2023  Band 16, Heft 3, Seite(n) 100761

    Abstract: Background: Anaphylaxis is a very dynamic issue with its incidence and trigger profile changing over the years. We aimed to compile the characteristics of anaphylaxis cases diagnosed in our clinic prospectively and to make a comparison between ... ...

    Abstract Background: Anaphylaxis is a very dynamic issue with its incidence and trigger profile changing over the years. We aimed to compile the characteristics of anaphylaxis cases diagnosed in our clinic prospectively and to make a comparison between diagnostic criteria proposed by National Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network (NIAID/FAAN) and World Allergy Organization (WAO).
    Method: Three-item diagnostic criteria recommended by NIAID/FAAN (2006) were used in the diagnosis of anaphylaxis. The clinical features of the cases, risk factors, etiologies, severity of anaphylaxis, and treatment approach were determined. The same patients were also classified by current WAO diagnostic criteria.
    Results: A total of 204 patients (158F/46 M, median age 45.3 years) were included. Drugs (65.2%), venom (9.8%) and food allergies (9.3%) were the top 3 etiologies. Among drug triggers, chemotherapeutics were the most common (17.7%), followed by antibiotics (15.3%) and non-steroidal anti-inflammatory drugs (14.2%). The patients were mostly diagnosed with the second criterion (84.8%), followed by the first criterion (11.8%) and the third criterion (3.4%) of the NIAID/FAAN criteria. In terms of WAO criteria, 82.8% of the patients were diagnosed with the first criterion, and 14.3% with the second criterion while 2.9% of the patients did not meet the WAO criteria. The severity of anaphylaxis was evaluated as grade-2, 3 and 4 in 30.9%, 64.2%, and 4.9% of the patients, respectively. Adrenaline was administered to 31.9% of the patients especially who had angioedema and bronchospasm (p = 0.04).
    Conclusion: Our data suggest that covering more details in patient's history may prevent possible underdiagnosis and WAO diagnostic criteria seem to be insufficient in some patients. We believe that our results will contribute to the literature on anaphylaxis and would be groundwork for future studies.
    Sprache Englisch
    Erscheinungsdatum 2023-04-01
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2581968-9
    ISSN 1939-4551
    ISSN 1939-4551
    DOI 10.1016/j.waojou.2023.100761
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: What happens to basophils and tryptase, LXA

    Çelik, Gülfem E / Aydin, Ömür / Güloğlu, Deniz / Seçil, Derya / Melli, Mehmet / Doğu, Figen / Ikinciogullari, Aydan / Sin, Betül A / Demirel, Yavuz / Misirligil, Zeynep

    The Journal of asthma : official journal of the Association for the Care of Asthma

    2022  Band 60, Heft 8, Seite(n) 1524–1534

    Abstract: Introduction: Aspirin desensitization (AD) is an effective treatment in patients with non-steroidal anti-inflammatory drugs (NSAID)-exacerbated respiratory disease (NERD) by providing inhibitory effect on symptoms and polyp recurrence. However, limited ... ...

    Abstract Introduction: Aspirin desensitization (AD) is an effective treatment in patients with non-steroidal anti-inflammatory drugs (NSAID)-exacerbated respiratory disease (NERD) by providing inhibitory effect on symptoms and polyp recurrence. However, limited data is available on how AD works. We aimed to study comprehensively the mechanisms underlying AD by examining basophil activation (CD203c upregulation), mediator-releases of tryptase, CysLT, and LXA
    Methods: The study was conducted in patients with NERD who underwent AD (group 1:
    Results: All baseline parameters of CD203c and LTB
    Conclusion: Although basophils are active during the first 3 months of AD, no releases of CysLT, tryptase or LXA
    Mesh-Begriff(e) Humans ; Basophils/metabolism ; Tryptases/metabolism ; Tryptases/pharmacology ; Asthma/metabolism ; Desensitization, Immunologic/methods ; Aspirin/adverse effects ; Aspirin/metabolism
    Chemische Substanzen Tryptases (EC 3.4.21.59) ; Aspirin (R16CO5Y76E)
    Sprache Englisch
    Erscheinungsdatum 2022-12-30
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603816-5
    ISSN 1532-4303 ; 0277-0903
    ISSN (online) 1532-4303
    ISSN 0277-0903
    DOI 10.1080/02770903.2022.2156352
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice.

    Engin, Ayse / Oktelik, Fatma B / Gelincik, Aslı / Sin, Aytul / Sin, Betul A / Dursun, Berna A / Beyaz, Sengul / Gorgulu, Begum / Cetin, Esin / Deniz, Gunnur

    Allergy and asthma proceedings

    2021  Band 42, Heft 4, Seite(n) 350–356

    Abstract: Background: ...

    Abstract Background:
    Mesh-Begriff(e) Allergens ; Animals ; Arthropod Venoms ; Bee Venoms ; Humans ; Hymenoptera/immunology ; Hypersensitivity/diagnosis ; Immunoglobulin E ; Insect Bites and Stings/diagnosis ; Wasp Venoms
    Chemische Substanzen Allergens ; Arthropod Venoms ; Bee Venoms ; Wasp Venoms ; Immunoglobulin E (37341-29-0)
    Sprache Englisch
    Erscheinungsdatum 2021-06-29
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1312445-6
    ISSN 1539-6304 ; 1088-5412
    ISSN (online) 1539-6304
    ISSN 1088-5412
    DOI 10.2500/aap.2021.42.210024
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Omalizumab in non-allergic Asthma: A report of 13 cases.

    Çelebi Sözener, Zeynep / Aydın, Ömür / Mısırlıgil, Zeynep / Mungan, Dilşad / Demirel, Yavuz Selim / Çelik, Gülfem E / Sin, Betül A / Bavbek, Sevim

    The Journal of asthma : official journal of the Association for the Care of Asthma

    2017  Band 55, Heft 7, Seite(n) 756–763

    Abstract: Background: There are limited data regarding the effectiveness of omalizumab in patients with non-allergic asthma.: Objective: To evaluate the clinical and functional effectiveness of omalizumab in patients with non-allergic asthma.: Methods: The ... ...

    Abstract Background: There are limited data regarding the effectiveness of omalizumab in patients with non-allergic asthma.
    Objective: To evaluate the clinical and functional effectiveness of omalizumab in patients with non-allergic asthma.
    Methods: The study was a single-center, retrospective chart review of patients with non-allergic asthma who were treated with add-on omalizumab between February 2014 and March 2016. After omalizumab was started, data of the asthma control test (ACT), pulmonary function test, and daily oral corticosteroid (OCS) dosage were collected at baseline, 16 weeks, 1 year, 2 and 3 years (if available). The number of exacerbations/hospitalizations were collected 1 year prior to and 6 months/1 year after omalizumab. To calculate the total daily dosage of OCS in milligrams, data for 6 months/1 year prior and after omalizumab treatment were recorded.
    Results: Thirteen patients were included. After omalizumab, the mean ACT was significantly increased at 16 weeks (n = 13, p = 0.002), 1 year (n = 7, p = 0.006), and 2 years (n = 5, p = 0.006). The mean daily OCS dose was significantly decreased at 16 weeks (n = 13, p = 0.001), 1 year (n = 7, p = 0.006), and 2 years (n = 5, p = 0.04). The mean number of exacerbations and hospitalizations were decreased at the 6th month (n = 13; p = 0.001, p = 0.005) and 1st year (n = 7; p = 0.01, p = 0.02). The mean total quantity of OCS decreased 42% from 1.4 to 0.8 g in the six-month period prior to and post-omalizumab treatment (n = 6, p = 0.02) and decreased 76% from 3.8 to 0.9 g at 1 year in the pre vs. post-omalizumab treatment comparison (n = 7, p = 0.01). Six (46.2%) patients responded perfectly and seven (53.8%) partially responded to treatment.
    Conclusion: Omalizumab can be effective in non-atopic severe asthma.
    Mesh-Begriff(e) Adult ; Anti-Asthmatic Agents/administration & dosage ; Asthma/diagnosis ; Asthma/drug therapy ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Omalizumab/administration & dosage ; Respiratory Function Tests ; Retrospective Studies ; Severity of Illness Index ; Treatment Outcome
    Chemische Substanzen Anti-Asthmatic Agents ; Omalizumab (2P471X1Z11)
    Sprache Englisch
    Erscheinungsdatum 2017-09-12
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 603816-5
    ISSN 1532-4303 ; 0277-0903
    ISSN (online) 1532-4303
    ISSN 0277-0903
    DOI 10.1080/02770903.2017.1362427
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Reliability of basophil activation test using CD203c expression in diagnosis of pollen allergy.

    Özdemir, Seçil Kepil / Güloğlu, Deniz / Sin, Betül A / Elhan, Atilla H / Ikincioğulları, Aydan / Mısırlıgil, Zeynep

    American journal of rhinology & allergy

    2011  Band 25, Heft 6, Seite(n) e225–31

    Abstract: Background: CD203c is a basophil surface marker and its expression is rapidly up-regulated after cross-linking of high-affinity immunoglobulin E (IgE) receptor (FcepsilonR1) by an allergen. CD203c basophil activation tests have been studied for the in ... ...

    Abstract Background: CD203c is a basophil surface marker and its expression is rapidly up-regulated after cross-linking of high-affinity immunoglobulin E (IgE) receptor (FcepsilonR1) by an allergen. CD203c basophil activation tests have been studied for the in vitro diagnosis of several allergic conditions. However, there is limited data about its diagnostic usefulness. The optimum allergen concentrations for stimulation and allergen specific cutoff values remain unknown for a number of allergens. This study was designed to investigate the efficacy of basophil activation test via CD203c in the diagnosis of pollen allergy.
    Methods: The CD203c basophil activation was determined in 31 allergic rhinitis patients with pollen allergy and 9 healthy nonatopic controls during the off-season. CD203c expression was evaluated using three-color staining protocol by flow cytometry.
    Results: After an in vitro stimulation with grass pollen extract, the CD203c assay clearly discriminated pollen-allergic patients from controls (p < 0.001). A dose-dependent increase in the percentages of CD203c-activated basophils was shown in rhinitis patients with pollen allergy (p < 0.001). The sensitivity and specificity was 100% and optimal cutoff values were 14.05 and 10.05% with 45.1 and 4.5 μg/mL Phl p 5 stimulation, respectively. Although the specificity was also 100%, the sensitivity was 93 and 87% and the cutoff values were 5.40 and 5.35% with 4.5 × 10(-4) and 4.5 × 10(-5) micrograms/mL Phl p 5 stimulation, respectively.
    Conclusion: The CD203c basophil activation test seems to be a reliable tool in the diagnosis of grass pollen allergy. It could be used when conventional diagnostic tests fail or can not be performed.
    Mesh-Begriff(e) Adult ; Basophil Degranulation Test ; Basophils/immunology ; Basophils/metabolism ; Basophils/pathology ; Cells, Cultured ; Feasibility Studies ; Female ; Humans ; Immunization ; Male ; Middle Aged ; Phosphoric Diester Hydrolases/analysis ; Plant Extracts/immunology ; Plant Proteins/immunology ; Poaceae ; Pollen/immunology ; Predictive Value of Tests ; Prognosis ; Pyrophosphatases/analysis ; Rhinitis, Allergic, Seasonal/diagnosis ; Rhinitis, Allergic, Seasonal/immunology ; Rhinitis, Allergic, Seasonal/physiopathology ; Sensitivity and Specificity
    Chemische Substanzen ENPP3 protein, human ; Phl p V protein, Phleum pratense ; Plant Extracts ; Plant Proteins ; Phosphoric Diester Hydrolases (EC 3.1.4.-) ; Pyrophosphatases (EC 3.6.1.-)
    Sprache Englisch
    Erscheinungsdatum 2011-11
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2482804-X
    ISSN 1945-8932 ; 1945-8924
    ISSN (online) 1945-8932
    ISSN 1945-8924
    DOI 10.2500/ajra.2011.25.3723
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang